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Beta-caroteneHumanin (HN) is a recently identiﬁed neuroprotective and antiapoptotic peptide derived from a portion of
the mitochondrial MT-RNR2 gene. We provide bioinformatic and expression data suggesting the existence of
13 MT-RNR2-like nuclear loci predicted to maintain the open reading frames of 15 distinct full-length HN-like
peptides. At least ten of these nuclear genes are expressed in human tissues, and respond to staurosporine
(STS) and beta-carotene. Sequence comparisons of the nuclear HN isoforms and their homologues in other
species reveal two consensus motifs, encompassing residues 5–11 (GFS/NCLLL), and 14–19 (SEIDLP/S).
Proline vs serine in position 19 may determine whether the peptide is secreted or not, while threonine in
position 13 may be important for cell surface receptor binding. Cytoprotection against the STS-induced
apoptosis conferred by the polymorphic HN5 variant, in which threonine in position 13 is replaced with
isoleucine, is reduced compared to the wild type HN5 peptide.© 2009 Elsevier Inc. All rights reserved.Introduction
Humanin (HN) is a recently discovered 24-amino acid peptidewith
cytoprotective properties, involving several distinct mechanisms. It
was initially identiﬁed as a neuroprotective factor against Alzheimer's
disease (AD)-speciﬁc triggers [1]. Neuroprotection is mediated
through the inhibition of the c-Jun (JUN) N-terminal kinase (JNK)
[2], tyrosine kinases and STAT3 or STAT3-related transcription factors
[3], and/or extracellular signal-regulated kinase (ERK [MAPK1])
pathway [4], and requires the interaction of HN dimers [5] with cell
surface receptors [6]. AlthoughHN is a high-afﬁnity ligand of G-protein
coupled formyl peptide receptors, formyl peptide receptor-like 1 and
2 (FPRL1 [FPR2] and FPRL2 [FPR3]) [7], and was shown to protect
FPRL1 (FPR2)-expressing neuroblasts from amyloid-beta42(Aβ42)-
induced apoptosis [8], the exact mechanisms linking FPRL1 (FPR2)
and FPRL2 (FPR3) with HN-mediated neuroprotection are unknown,
and additional HN-speciﬁc receptors have been postulated [3]. Neuro-
protection may partially be attributed to the interaction of HN with
insulin-like growth factor-binding protein 3 (IGFBP-3). IGFBP-3 was
also suggested to serve as theHNtransporter in both the circulation and
tissues, reminiscent of its carrier function for the insulin-like growth
factors (IGFs) [9]. The cytoprotective effects of HN are not conﬁned to
neurons, and involve other components of the brain (rescue of human
cerebrovascular smoothmuscle cells from Aβ-induced toxicity [10]) as
well as extraneural tissues (prolonged survival of serum-deprived ratll rights reserved.pheochromocytoma cells [11], and human lymphocytes [12] and
muscular cells [13]). Delayed apoptosis of serum-deprived leukemia
K562 cells was found dependent upon the inhibition of the p38 sig-
naling pathway [14]. Whereas HN secretion and extracellular receptor-
binding seem critical for neuroprotection, HN is also a potent
intracellular inhibitor of apoptosis, interacting with the members of
the BCL2/BAX proapoptotic protein family, BAX [15], BID, tBID [16], and
BIMEL (BCL2L11) [17], and interfering with the activation of this
pathway. Moreover, there is some evidence suggesting that HN can act
directly on the mitochondria to increase the ATP production,
independent of BAX inactivation [13]. The intracellular HN level may
be controlled, at least in part, by the ubiquitin-mediated protein
degradation pathway through the interaction with the tripartite motif
protein 11 (TRIM11) [18].
Increased expression of the HN peptide observed in the AD brains
[1], synovial cells affected with the diffuse type pigmented villonod-
ular synovitis [19], and skeletal muscles from patients with mitochon-
drial disorders [20,21] suggests that HN is part of the physiological
mechanisms promoting cell survival under stressful conditions, such
as neurodegeneration, inﬂammation, or energy deﬁciency. Consis-
tently, the exogenous administration of the more potent synthetic HN
derivative, Gly14-HN (HNG), improved experimentally-induced
impairments of learning and memory [22], spatial memory [23], as
well as behavioral deﬁcits [24] in rodents, and reduced the volume of
cerebral infarct in a murine model of stroke [4,25]. These in vivo
effects of HNG may involve the inhibition of neuroinﬂammation [24],
and activation of the PI3K/Akt pathway [25].
Further modiﬁcations of HNG led to the creation of even more
active analogues, including AGA-(C8R)HNG [26] and its derivatives, as
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neurotrophic factor [27]. These new peptides were shown to improve
quinuclidinyl benzilate-induced spatial memory impairment in rats
[28], and prolong survival of the amyotrophic lateral sclerosis model
mice [29].
While there is compelling evidence for the endogenous HN
synthesis [30], the exact location of the gene (or genes) encoding the
peptide has not been determined conclusively. The originally iden-
tiﬁed 1567-base cDNA containing the open reading frame (ORF) of
HN is 99% identical with a fragment of the MT-RNR2 gene, coding for
the 16S subunit of the mitochondrial rRNA [1], which gave rise to
speculations that HN might be translated from the mitochondrial 16S
rRNA with a polyA tail [26]. Should the translation occur in the
mitochondrium rather than cytoplasm, the usage of the mitochon-
drial genetic code would result in a premature stop codon and slightly
shorter peptide, lacking the last three carboxy-terminal amino acids.
However, even such abbreviated peptide was fully functional in
regard to the inhibition of the BAX-mediated proapoptotic pathway
[15]. Alternatively, HN could be encoded within one or more of the
nuclear regions with 92–95% similarity to the original HN cDNA,
dispersed in multiple copies throughout the human genome [1,15],Fig. 1. Genomic localization, speciﬁc primer sequences for quantitative RT-PCR, and tissue
Black columns indicate expression levels of each isoform in different tissues as a percent of th
are ordered according to the decreasing overall amount of the transcript in the testis, though
each other, and this is only an approximation. The isoforms encoded byMTRNR2L11,MTRNR2
putative novel peptide-coding genes were consulted with and approved by Human Genomthough they have not been analyzed systematically for their coding
potential so far.
In this report, we present bioinformatic evidence for the existence
of at least 13 distinct human nuclear loci that maintain the ORFs for a
host of putative full-length (i.e. 24-amino acid-long or longer) HN-like
peptides. We also provide gene expression data showing that at least
ten of them might be functional genes regulated in a tissue- and
factor-speciﬁc manner. Additionally, we synthesized two of these
peptides and proved their antiapoptotic properties.
Results
Putative HN isoforms encoded by the nuclear genes
The BLASTN searches yielded 28 nuclear sequences highly
homologous with the MT-RNR2 HN ORF dispersed throughout the
human genome. Following the translation with the standard genetic
code 13 of them proved to maintain the ORFs of full-length HN-like
peptides. The remaining 15 sequences apparently could not generate
functional peptides due to a premature stop codon (most often at
codon 4) or lack of a consensus translation start site (ATG). Theexpression proﬁles of the putative nuclear MT-RNR2-like genes encoding HN isoforms.
e rate in the testis, which was used as a comparator and considered 100%. The isoforms
the expression analysis was not speciﬁcally designed to compare the isoforms between
L12, andMTRNR2L13 were not expressed in any of the studied tissues. All names of the
e Nomenclature Committee.
Fig. 3. Multiple sequence alignment of the predicted chimpanzin peptides encoded by
(PANTR)MT-RNR2 and putative (PANTR)MT-RNR2-like nuclear genes. Alignment was
done by ClustalW and rendered graphically by BOXSHADE 3.21. Identical and similar
amino acids are highlighted in black and gray, respectively. There aremultiple tandemly
repeated copies of MTRNR2L17 in chromosome Y.
249M. Bodzioch et al. / Genomics 94 (2009) 247–256approximate chromosomal locations and tissue expression proﬁles
(see below) of all theMT-RNR2-like genes with a coding potential are
shown in Fig. 1, while the predicted amino acid sequences of their
putative products are aligned in Fig. 2.
The predicted HN peptides show a high degree of conservation
with amino acid positions 1, 6, 8, 9, 10, 11, 17, 18, 21, and 22 identical in
all the isoforms, including the prototype mitochondrial HN (HNM)
encoded by theMT-RNR2 gene. Well conserved are also positions 5, 7,
15, 16, and 19, which only occur in two variants. The most variable
(three or more variants) are amino acids 2, 3, 4, 12, 13, 14, 20, 23, and
24. Isoforms HN2 and HN4 encoded by the MTRNRL2 and MTRNR2L4
genes, respectively, are predicted to have four additional carboxy-
terminal amino acids. Despite a high degree of homology every
isoform has a unique amino acid sequence except for identical HN8
and HN12 encoded by the MTRNR2L8 and MTRNR2L12 genes,
respectively. However, there is a polymorphic site (rs7350541) within
MTRNR2L8, predicted to cause the Ser12Leu amino acid exchange, and
produce a peptide sequence identical to the prototype HNM. We
identiﬁed another polymorphic site (rs11004928) within the putative
MTRNR2L5 gene, changing threonine to isoleucine in amino acid
position 13 (Thr13Ile) of HN5. Taking into account these polymorphic
variants, there might be as many as 15 distinct HN peptides encoded
by MT-RNR2-like nuclear genes.
Homologues of nuclear MT-RNR2-like genes in other species
We identiﬁed 14 putative full-length chimpanzins, i.e. HN homo-
logues in the chimpanzee, encoded in its nuclear genome (Fig. 3). They
are all well-conserved with some positions showing moderate
variability in a pattern very similar to that in humans. There is a
considerable overlap between human and chimpanzee MT-RNR2-like
genes as evidenced by the phylogenetic analysis (Fig. 4). Most of
these genes are located in syntenic chromosomal regions and have the
same or nearly-identical amino acid sequences in both species.
However, there are also important differences. Human MTRNR2L1,
MTRNR2L2, MTRNR2L6, and MTRNR2L9 genes do not have their
counterparts in the chimpanzee genome,while there are fouradditional
genes in the chimpanzee, which are absent in humans, including
(PANTR)MTRNR2L14, (PANTR)MTRNR2L15, (PANTR)MTRNR2L16, and
the unique multi-copy (PANTR)MTRNR2L17 in sex chromosome Y
predicted to encode a peptide with an extra asparagine between
the conserved residues 17 and18 (PANTR)MT-RNR2, (PANTR)MTRNR2L2,
(PANTR)MTRNR2L6, (PANTR)MTRNR2L8, and(PANTR)MTRNR2L14 appar-
ently encode the same peptide identical with HN8 and HN12.Fig. 2.Multiple sequence alignment of the predicted HN peptides. Alignment was done
by ClustalW and rendered graphically by BOXSHADE 3.21. Identical and similar amino
acids are highlighted in black and gray, respectively. “M” indicates the mitochondrial
isoform, while numbers refer to chromosomes, in which the nuclear isoforms are
located. The two HN loci in chromosome 10 are distinguished by “a” and “b”. The two
polymorphic variants of HN10b are indicated as T13 and I13. The isoforms that were not
expressed in any of the studied tissues are marked with #.In the nuclear genome of the Rhesusmonkey (Macacamulatta), we
found as many as 20 different MT-RNR2-like loci with a coding
potential. The predicted Rhesus peptides differ from the HNs and
chimpanzins more that the latter two between themselves but share a
similar pattern of conserved residues (Fig. 5). Interestingly, the
mitochondrial isoform lacks a consensus translation initiation site
(either nuclear or mitochondrial), though the normal ATG codon is
present in the mitochondrial gene of the closely related Barbary
macaque (Macaca sylvanus). Unlike in primates, the nuclear MT-
RNR2-like loci seem very infrequent in other organisms; we only were
able to identify single nuclear loci with a coding potential in some
mammalian species, including a cow, a dog, and a mouse (Fig. 6).
However, the mitochondrial sequences maintaining the ORFs of
peptides similar to HN are relatively well-conserved in mtDNA,
where they can be traced down the whole evolutionary tree. Similarly
to the Rhesus monkey, mice lack a valid translation start site within
the mitochondrial homologue, though they have a nuclear gene
predicted to code for a peptide with 13 additional carboxy-terminal
amino acids. On the other hand, rats apparently have no coding
nuclear genes but possess a mitochondrial gene with the consensus
ATG translation start site. Dependent upon the usage of the
mitochondrial vs standard genetic code, the putative mitochondrial
homologues in a cow, a dog, and a rat (and possibly amouse, if the lack
of a valid translation start site is neglected) could produce alternative
products distinguished by the presence or absence of the carboxy-
terminal tail of between 11 and 23 amino acids.
Tissue expression proﬁles of the MT-RNR2-like genes
Speciﬁc mRNA species of ten of the 13 putative nuclear MT-RNR2-
like genes were detectable in one or more of the studied tissues
(Fig. 1). We could not conﬁrm the expression of MTRNR2L11,
MTRNR2L12, or MTRNR2L13. The remaining genes, including MT-
RNR2, were generally highly expressed in the testis, kidney, heart,
skeletalmuscles, and brain, and had lowexpression in the liver, thyroid
gland, or bone marrow. The most consistent feature was high
expression of all the isoforms in the testis. MT-RNR2, MTRNR2L1,
MTRNR2L8, and MTRNR2L9 were notable for high expression in the
kidney and heartmuscle, whichmatched or exceeded that in the testis.
MTRNR2L7 was only detectable in the testis, while MTRNR2L5 was
additionally expressed in the brain, MTRNR2L6 – in skeletal muscles,
and MTRNR2L10 – in the mature brain and thyroid gland. MTRNR2L8
was not expressed in skeletal muscles despite high expression in the
heart. Since the analysis was primarily designed to obtain the isoform-
speciﬁc patterns of relative expression in different tissues, direct
comparison of the isoforms between each other could only be used for
Fig. 4. The phylogenetic tree of the putative genes encodinghumanin and chimpanzinpeptides. ⁎There aremultiple tandemly repeated copies of (PANTR)MTRNR2L17 in chromosomeY.
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studied tissues the expression of MT-RNR2 was considerably higher
than of any of the nuclear isoforms. In the testis, the difference ranged
roughly from 100-fold (MT-RNR2 compared to MTRNR2L1) up to
250,000-fold (MT-RNR2 compared toMTRNR2L10).
Expression response to pro- and antiapoptotic stimuli in human
umbilical vein endothelial cells (HUVECs)
Since endothelial cells were not included in the standardized human
RNA panel described above, we ﬁrst measured the baseline expression of
the putativeMT-RNR2-like genes in HUVECs, and found that it was high
for all the isoforms except forMTRNR2L11,MTRNR2L12, andMTRNR2L13,
which apparentlywerenotexpressed, similar to theother studied tissues.
STS (Fig. 7A)
At 6 h, the proapoptotic STS downregulated all of the isoforms leading
toamaximumsix-folddecrease in theexpressionofMTRNR2L2. However,
for MT-RNR2 and MTRNR2L4, this effect was small and not signiﬁcant.
After 24 h, the trend was reversed and all the genes became upregulated
compared to the baseline with the strongest effect (eight-fold or more)
noted forMTRNR2L3,MTRNR2L6,MTRNR2L8, andMTRNR2L9 (Fig. 7A).
Beta-carotene (Fig. 7B)
In HUVECs, beta-carotene inhibits BAX and acts as an antiapoptotic
factor [32]. Followinga six-hour incubationwith this agent all of thegenes
became downregulated (2–8-fold) except forMTRNR2L2, whose expres-
sion increased eight-fold. At 24 h, MT-RNR2, MTRNR2L4, and MTRNR2L5
remained downregulated, while MTRNR2L2 decreased to the baseline.
The expression of the remaining genes increased, either returning to the
baseline (MTRNR2L6,MTRNR2L7,MTRNR2L8,MTRNR2L9), or rising more
than eight-fold above the baseline (MTRNR2L3,MTRNR2L10) (Fig. 7B).
Selection of HN peptides for functional studies
In order to prove the biological activity of peptides encoded by the
nuclear genes we synthesized and tested two of them. We selected thepolymorphic variants of HN5, encoded by the MTRNR2L5 gene, differ-
entiated by threonine or isoleucine in amino acid position 13. This selec-
tionwas based on: 1) evidence that Thr13maybe critical for bindingwith
cell surface receptors and neuroprotective activity [31,32], and 2) the fact
that Thr13Ile HN5 polymorphism represents a natural genetic variance,
and thusmay be relevant to human health. However, before undertaking
the functional tests, we estimated the occurrence of both variants in the
general population to rule out a very low frequency of aminor allele (see
the next section). In addition to Thr13- and Ile13-HN5, we also synthe-
sized the high-activity HNG and prototype HNM peptides as controls.
Genotyping the HN10b gene
Among the 93 healthy adult unrelated individuals 34 (36.5%) were
homozygous for Thr13-HN5, 13 (14.0%) were homozygous for Ile13-
HN5, while the remaining 46 (49.5%) were heterozygous. Thus, both
alleles are common in the general population with frequencies of
61.3% and38.7% for the Thr13-HN5and Ile13-HN5variants, respectively.
Functional imaging
The 24-hour preincubation with HN peptides (HNG, HNM, Thr13-
HN5, or Ile13-HN5; 4 μM ﬁnal conc.) protected HUVECs against the
proapoptotic effects of STS, slowing the rate of the TMRM signal
decrease (which reﬂected compromise of the mitochondrial function)
and delaying morphological changes of the cells. Fig. 8 illustrates
changes of the densitometry sum parameter (DSP), which is a
composite measure of TMRM signal intensity and cell integrity
(mean intensity×ROI area, where ROI is a cytoplasmic region adjacent
to an identiﬁable nucleus), 2 h following the administration of
0.01 μM, 0.03 μMand 0.1 μMSTS. The rate of DSP decreasewith a rising
STS concentration was similar in cells preincubated with HNG, HNM,
and Thr13-HN5. However, in cells preincubated with Ile13-HN5 the
DSP reduction was much greater, especially with the highest STS
concentration.
When monitoring HUVECs with serial scans during the two-hour
period of exposure to STS,we observed that STS-inducedmorphological
Fig. 5.Multiple sequence alignment of the predicted homologues of the HN peptides in
the Rhesus monkey (Macaca mulatta). Alignment was done by ClustalW and rendered
graphically by BOXSHADE 3.21. Identical and similar amino acids are highlighted in
black and gray, respectively. “M” indicates the mitochondrial isoform; the other
isoforms are encoded by putative nuclear genes. Although there is no valid translation
initiation signal in the mitochondrial isoform in the Rhesus monkey, a regular
methionine codon can be found in the closely related Barbary Macaque (Macaca
sylvanus) (Ms).
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in those preincubated with Ile13-HN5. Fig. 9 shows HUVECs stained
with TMRM and Hoechst 30min following the administration of 0.1 μM
STS. The cells preincubatedwith Thr13-HN5 seem still intact (Fig. 9, left
panel), while many of those, that were preincubated with Ile13-HN5,
begin to demonstrate cytoplasm shrinkage (Fig. 9, right panel).
Discussion
HN, a potent neuroprotective and antiapoptotic agent, is produced
endogenously [26], but the exact location (mitochondrial vs nuclear)
of the gene (or genes) encoding it remains elusive. The prototype
coding sequence was identiﬁed within a portion of MT-RNR2, but the
mechanismwhereby this cytoplasmic and secretory peptide might be
translated from the mitochondrial gene has not been plausibly
explained. Alternatively, HN could originate from one or more of the
highly homologous nuclearMT-RNR2-like sequences, which, however,
have never been analyzed systematically, especially in regard to their
coding potential. In this study, we scanned the nuclear genome and
identiﬁed 13 distinct loci predicted to maintain ORFs of full-length
HN-like peptides. According to the current concepts, these sequences
could be classiﬁed as the nuclear mtDNA (NUMT). NUMTs are
fragments of mtDNA incorporated into the nuclear genome in a
process supposedly mediated by repetitive or transposable elements
[33]. There are between 247 and 612 NUMTs in the human genome
[33,34]. Although NUMTs are considered pseudogenes [33–35], we
found some bioinformatic and experimental evidence suggesting that
at least some of the nuclear MT-RNR2-like sequences might be
functional genes.
The peptides predicted to be encoded by these genes share a
characteristic pattern of conserved and variable residues, but
generally are not mutually redundant. Comparisons of the HN
isoforms encoded by the nuclear genes among themselves and with
their homologues in other species helped deﬁne two majorconsensus motifs, encompassing the positions 5–11 (GFS/NCLLL),
and 14–19 (SEIDLP/S), complemented with two invariable amino
acids in positions 21 and 22 (KR). These motifs largely overlap the
amino acids proven critical for various HN functions in earlier
experiments with mutant HNs, in which wild type residues were
serially replaced with alanine, arginine, or asparagine [31,32,36]. The
former motif contains three consecutive leucine residues, which
constitute a core domain for the signal peptide activity and are
essential for the secretion of the full-length HN from the cell [31].
Secretory properties are also dependent upon Pro19 and Val20 [32].
Among the HN isoforms encoded by the MT-RNR2-like genes, Val20
is often substituted with similar nonpolar amino acids, while in
position 19 proline is approximately as frequent as serine (Fig. 2).
Pro19Arg mutants were defective in self-secretion [32], and it can be
hypothesized that the exchange of proline for another polar amino
acid, such as serine, might have the same effect. Additionally, Pro19
is one of the eight amino acids essential for the HN-mediated
neuroprotection [31,32]. They also include highly conserved Ser7,
Cys8, Leu9, and Ser14, as well as more variable Pro3, Leu12, and
Thr13. Interestingly, in most of the HN isoforms encoded by the
putative MT-RNR2-like genes, Pro19 associates with “neuroprotec-
tive” Pro3 and Thr13, while Ser19 is most often accompanied by Thr3
and Ile13. This observation may help interpret the results of the
earlier studies, which revealed that the neuroprotective activity
requires HN secretion and binding with cell surface receptors [6],
and that HN also acts intracellularly through the interaction with
BAX and other proteins of the BCL2 family [15]. We postulate that
there might be two functional groups of HN peptides differentiated
by proline vs serine in position 19. The Pro19 group would be
secreted to bind with the cell surface receptors with high afﬁnity
conferred by the full consensus sequence for neuroprotection. On the
other hand, the Ser19 group would remain in the cytoplasm available
for the interaction with BAX and related proteins. However, if this
assumption were true, there would be serine rather than leucine in
position 12 contributing to the neuroprotective sequence. Thus, the
neuroprotective function of the HN isoforms might be determined by
Pro3, Ser12, and Thr13 for receptor binding, and Pro19 for secretion.
Mutations of the other positions implicated in neuroprotection could
be deleterious because of the disruption of the conserved backbone
and/or loss of the ability to dimerize.
The requirement of Thr13 for receptor binding may explain our
observation that the Ile13-HN5 variant has reduced cytoprotective
activity against STS-induced apoptosis compared to the wild type
Thr13-HN5 peptide in HUVECs. It may also be true for other cell types,
including neurons. Therefore, the HN5 polymorphic variant with
isoleucine rather than threonine in amino acid position 13 may be a
risk factor in neurodegeneration, or, more broadly, in any conditions
associated with insufﬁciency of cellular prosurvival mechanisms. The
high frequency of both HN5 alleles makes this polymorphism a
practical candidate for inclusion in gene association studies.
By detecting speciﬁc mRNA species in several tissues and
demonstrating their dynamic response to pro- and antiapoptotic
stimuli in HUVECs, we provided evidence suggesting that at least
some of the nuclear MT-RNR2-like sequences are expressed and may
code for true peptides. However, the gene expression experiments
pose several problems and have important limitations. Firstly, the
design and optimization of speciﬁc primer pairs for quantitative RT-
PCR is difﬁcult because of very high sequence homology. Secondly, the
detection of mRNA does not prove that it is undoubtedly translated
into protein, and provides only indirect information on possible
posttranslational modiﬁcations. Thirdly, the ampliﬁcation products
may not necessarily represent functional mRNA molecules of the MT-
RNR2-like genes. For example, they could be transcribed fragments of
other functional units (intronic sequences in immature mRNA species,
functional RNAs, etc.) or constitute some form of illegitimate
expression. Nevertheless, despite the inherent difﬁculties in primer
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probably the only practical means of differentiating so closely related
genes. While single nucleotide differences are usually enough to
design speciﬁc primer sets, it would be very difﬁcult (if not
impossible) to raise antibodies with a matching degree of discrimi-
nating power. Moreover, in order to minimize the risk of sample
contamination with genomic DNA or immature mRNA intermediates,
we isolated total RNA from HUVECs, having ﬁrst removed their nuclei,
and, subsequently, incubating the RNA samples with DNAses.
Nevertheless, the results of our functional experiments with two of
these peptides, representing synthetic HN5 variants, suggest that they
do possess biological activity, and the mRNA species detected in
various cells may indeed reﬂect true cellular processes.
We recorded the highest expression of the nuclearMT-RNR2-like in
the testis, heart, skeletal muscles, and brain, which is consistent with
the earlier reports on HN [6]. However, each gene had its own speciﬁc
tissue expressionpattern, as reviewed in detail in Results and Fig.1.We
could not detect speciﬁc mRNA species of MTRNR2L11, MTRNR2L12,
and MTRNR2L13. They may not be normally expressed in the studied
tissues or are true pseudogenes. MTRNR2L12 is predicted to have an
identical amino acid sequence as MTRNR2L8, and may be silenced to
avoid redundancy. The other two non-expressors are predicted to code
for peptideswith unique amino acids, Val12 inMTRNR2L11 and Asp2 in
MTRNR2L13, which do not occur in any of the other putative HN
peptides, and might represent inactivating mutations.
HN was previously shown to be induced by proapoptotic stimuli,
such as STS or serum deprivation [15], which act through the BAX-
dependent pathways. We checked how STS affects the expression of
MT-RNR2 and MT-RNR2-like genes in HUVECs. After 24 h all the
expressed genes were uniformly upregulated consistent with the cell
survival activity mediated by both the intracellular (the Ser19 group)
and extracellular (the Pro19 group) mechanisms. Surprisingly, the
initial response after 6 hwas quite opposite andwas characterized by a
decrease in expression of all the isoforms compared to the baseline.
These results suggest that acute insultsmay in fact compromise theHN
activity and reduce the cell survival potential initially. Therefore, the
HN-mediated protection may be more speciﬁc for prolonged pro-
cesses, such as neurodegeneration, inﬂammation, nutrient deﬁciency,
or chronic exposure to noxious stimuli. In a recent study, the admin-
istration of HNG resulted in the reduction of the infarct volume in a
murine model of stroke [4]. It can be hypothesized that the exogenous
HNG overcame the relative HN deﬁciency in acute brain ischemia.
Contrary to STS, the response to beta-carotene was quite varied.
We showed previously that beta-carotene prevents apoptosis in
HUVECs through the inhibition of the proapoptotic BAX [32], which is
also a target for the antiapoptotic activity of HN. According to our
speculations, the interaction with BAX might be mediated by some or
all of the Ser19 isoforms, whichmay lack the ability to exit the cell and
would remain in the cytoplasm. Noteworthy, the three nuclear MT-
RNR2-like genes with the highest expression response to beta-
carotene after 24 h, MTRNR2L3 (Neight-fold increase), MTRNR2L10
(Neight-fold increase), and MTRNR2L4 (nearly four-fold decrease),
actually belong to the Ser19 group. The link between beta-carotene
and HN may also involve the nuclear retinoid receptors, RXRα, one of
the targets of IGFBP3, which apparently is regulated by HN [9].
Our data are not enough to answer conclusively the original
question whether HN is or is not synthesized within the mitochondria
or can be translated from the mitochondrial mRNA on cytoplasmic
ribosomes. In some organisms, such as the Rhesus monkey or mouse,
the predicted mitochondrial gene lacks a valid translation initiation
signal (with either the standard or mitochondrial genetic code usage),
and would be unlikely to support the synthesis of a peptide. On the
other hand, in all our mRNA expression experiments, MT-RNR2
encoding for the prototype HNM was by far more activated than any
of the nuclearMT-RNR2-like genes, and showed amoderate response to
both STS and beta-carotene. However, theORFofHNM is locatedwithina functional mtDNA gene producing rRNA molecules, some of which
may have a polyA tail [26]. The presence of the polyA attachment need
not mean these RNA molecules are actually translated, but may be
responsible for their reverse transcription and ampliﬁcation in the
quantitative RT-PCR experiments. Therefore, the observed moderate
changes in “expression” of the peptide-coding MT-RNR2 may have in
fact reﬂected variations of the levels of the mitochondrial rRNA. More-
over, the relative abundance of the mitochondrial rRNA containing the
putative peptide-coding sequence could have effectively masked the
existence of highly homologous but signiﬁcantly less abounding
nuclearMT-RNR2-like mRNA species. This would explain the apparent
lack of sequences speciﬁc for the putative nuclearMT-RNR2-like genes
in the EST databases. A more indirect argument against the peptide-
coding potential of MT-RNR2 could also be made, pointing to the
fact that the synthesis of the peptide would have to be tightly linked
with the levels of the mitochondrial rRNA. Although this possibility
cannot be completely ruled out, especially as HN appears upregulated
in the proapoptotic conditions, which are also likely to affect the
mitochondria, itwould be difﬁcult to explain themultitude of functions
ascribed to HN by a single gene lacking independent mechanisms of
regulation.
Assuming, however, that the nuclear MT-RNR2-like genes are the
true and only source of the HN peptides, onewould have to admit that
the HN homologues encoded by the nuclear genes might be the
exclusive feature of the primates, or, at most, mammals. Multiple
isoforms seem unique for humans and monkeys, while in other
mammalian species there are only single nuclearMT-RNR2-like genes
per genome. In the rat, we were not able to identify any nuclear
sequences that would bear signiﬁcant resemblance to MT-RNR2.
However, despite the lack of direct evidence for the in vivo production
of rattin (no peptide detection experiments have been reported), the
predicted mitochondrial rat peptide with 15 extra residues not only
replicated the HN protection against the AD-speciﬁc insults, but
additionally showed protective activity toward excitotoxic neuronal
death [37]. On the other hand, as mentioned before, there is likely no
functional mitochondrial homologue in mice.
Materials and methods
Bioinformatic analysis
The human genome was searched with BLASTN (http://www.
ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=9606)
using the prototype cDNA sequence [1] derived from the MT-RNR2
gene as a query. Each hit was assessed for a coding potential of a full-
length peptide (24 amino acid-long or longer) and mapped according
to the NBCI Build 36.2. A similar procedure was used to detect nuclear
MT-RNR2-like sequences in other species.
Peptide synthesis
Peptides included in this study (HNG, HNM, Thr13-HN5, and Ile13-
HN5) were synthesized manually in a microwave reactor by the solid-
phase method using the 9-ﬂuorenylmethoxycarbonyl (Fmoc) chem-
istry (Lipopharm.pl, Zblewo, Poland). The completeness of each
coupling reaction was monitored by the chloranil test. The peptides
were cleaved from the solid support by triﬂuoroacetic acid (TFA) in the
presence of water (2.5%), and triisopropylsilane (2.5%) as scavengers.
The cleaved peptides were precipitated with diethyl ether. The
peptides were puriﬁed by solid-phase extraction using protocol
described previously [38]. The resulting fractions of purity greater
than 95–98% were tested by high performance liquid chromatography
(HPLC) and thin layer chromatography (TLC). The peptides were also
analyzed by matrix-assisted laser desorption ionization-time of ﬂight
mass spectrometry (MALDI-TOF). The peptides dissolvedwell inwater
andwere stored in stock 1 μg/ml water solutionwithout precipitation.
Fig. 6.Multiple sequence alignment of the predicted homologues of the HN peptides in non-primate mammalian species. “M” indicates the predicted long sequences of the putative
mitochondrial isoforms translated with themitochondrial genetic code, while “M⁎” refers to the shorter sequences obtained with the use of the standard genetic code. Numbers refer
to chromosomes, in which the nuclear isoforms are located. There are apparently no nuclear HN homologues in the rat, while the putative mitochondrial isoform in the mouse does
not have a consensus translation initiation signal.
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Human umbilical vein endothelial cells (HUVECs) were obtained
from healthy donors by trypsinization of the umbilical vein.Fig. 7. The changes in relative expression rates of the HN isoforms in HUVECs following 6-
represented as ΔΔCT, where one unit is equivalent to a two-fold change in expression. The is
BAX and related proteins, are shown by arrowheads.For gene expression experiments, they were cultured for 6 and 24 h
in fetal calf serum with 0.01 μM staurosporine (STS) or 3 μM beta-
carotene (dissolved in 0.075% tetrahydrofuran [THF] and 0.075%
ethanol). All-trans-beta-carotene was obtained from the chemicaland 24-hour exposure to 0.01 μM STS (A) or 3 μM beta-carotene (B). The results are
oforms from the Ser19 group, predicted to remain in the cytosol for the interaction with
Fig. 8. Dose-response curves representing changes of the TMRM signal densitometry sum parameter with increasing STS concentration in HUVECs preincubated with different HNs.
The cells were incubated for 24 h with HNG, HNM, Thr13-HN5, and Ile13-HN5 (all HNs in 4 μM ﬁnal conc.), or not pretreated with HN (no HN), and then exposed for 2 h to STS in
0.01 μM, 0.3 μM, or 0.1 μM concentration.
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STS was purchased from Sigma-Aldrich (Poznan, Poland). In order to
minimize beta-carotene oxidation and degradation all handling was
performed in dimmed light and cooled conditions from small aliquots
fractionated into argon-ﬁlled vials. In addition, THF and ethanol were
ﬁltered through the Alox columns to remove any traces of oxidizing
substances. THF is a common solvent for beta-carotene but can be
cytotoxic. We have shown previously that with the addition of ethanol
the THF concentration can be reduced without compromising beta-
carotene solubility, while the toxicity for HUVECs is minimized [32].
The induction and inhibition of apoptosis by STS and beta-carotene,
respectively, was conﬁrmed by Apo-ONE Homogeneous Caspase-3/7
Assay (Promega, Madison, WI, USA), consistent with the results of our
earlier experiments [39]. Cell necrosis was excluded by the LDH assay
(Cytotoxicity Detection Kit; Boehringer-Roche, Germany).
For live monitoring, HUVECs were seeded in 96-well clear bottom
tissue culture plates for imaging applications (Becton Dickinson,
Franklin Lakes, NJ, USA) at 10,000 cells per well to achieve 50%
conﬂuence and cultured for 24 h in fetal calf serumwith different HN
peptides, including HNG, HNM, Thr13-HN5, and Ile13-HN5, each in
4 μM ﬁnal concentration. Subsequently, the cells were exposed to
either 0.1 μM, 0.03 μM or 0.01 STS, and stained with tetramethylrho-Fig. 9. Live images of the TMRM-stained HUVECs preincubated with Thr13- and Ile13-HN5 a
4 μM Ile13-HN5 (right panel) imaged livewith BD Pathway 855 High-Content Bioimager (Bec
cells were stained with amarker of the mitochondrial function, TMRM (green), and a nuclear
Thr13-HN5 seem intact, many of those incubated with Ile13-HN5 begin to show cytoplasm
surround the nucleus, but are “shifted aside” exposing a “bare” nucleus (arrows in the righdamine methyl ester (TMRM; ﬁnal conc. 2 ng/μl) and Hoechst (ﬁnal
conc. 20 μM; both dyes from Molecular Probes, Carlsbad, CA, USA).
Serial imaging was performed with an automated high-throughput
microscope system, BD Pathway 855 High-Content Bioimager (Becton
Dickinson, Franklin Lakes, NJ, USA) using the 20×/NA 0.75 objective.
AttoVision 1.5 software was used to segment the cells into regions of
interest, and changes in ﬂuorescence intensity were analyzed with
Image Data Explorer 2.2.15 (both software packages from BD
Biosciences, San Jose, CA, USA).
Expression analysis
RNA sources
For the analysis of tissue expression proﬁles we used ten
standardized high-quality RNA species selected from the Human
Total RNAMaster Panel II (Clontech Laboratories, Inc., Mountain View,
CA, USA). In the STS/beta-carotene experiments, total RNA was
isolated from the cells using the RNeasy Mini Kit (QIAGEN, Hilden,
Germany). We applied the cytoplasmic protocol as described in the
product manual in order to ensure the exclusive isolation of the
mature mRNA species (without the admixture of nuclear mRNA
intermediates or genomic DNA).nd exposed to STS. HUVECs preincubated for 24 h with 4 μM Thr13-HN5 (left panel) or
ton Dickinson, Franklin Lakes, NJ, USA) 30min following the exposure to 0.1 μMSTS. The
dye, Hoechst (blue). Magniﬁcation×20. While the vast majority of cells pretreated with
shrinkage. In normal HUVECs, mitochondria located in the cytoplasm symmetrically
t panel) as an early response to STS.
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We used Primer Express 2.0 Software (Applied Biosystems, Foster
City, CA, USA) to design speciﬁc primer pairs amplifying each of the
putativeMT-RNR2-like genes maintaining the full ORF. Since the exact
limits of the transcribed sequences have not been determined the
primer pairs were located preferably within or very close to the
putative coding regions (the most likely to be transcribed in an active
gene). Despite a very high degree of homology it was possible to
design a unique primer set for each MT-RNR2-like gene taking
advantage of minor sequence differences between them, especially
placing the oligo's ﬁnal 3′ nucleotide at the discriminating position
(i.e. the one differing among the HN isoforms). Sequences of all
primers are provided in Fig. 1. The same Primer Express 2.0 Software
was used to design the primer pair for the calibrator (GAPDH; forward:
CCAGGCGCCCAATACGA; reverse: GCCAGCCGAGCCACATC). Speciﬁcity
of the ampliﬁcation products of allMT-RNR2-like genes and calibrator
were conﬁrmed by two-directional sequencing.
Ampliﬁcation conditions
Forty ng aliquots of total RNA were reversely transcribed with
oligo-dT primers using the Omniscript RT Kit (QIAGEN, Hilden,
Germany) and PCR ampliﬁed on the DNA Engine Opticon® 2
Continuous Fluorescence Detection System (MJ Research, Inc.,
Waltham, MA, USA) using the QuantiTect SYBR Green PCR Kit
(QIAGEN, Hilden, Germany) and standard recommended ampliﬁca-
tion conditions with the annealing temperature set to 59 °C. Each
experimental point was measured in triplicate.
Data analysis
We analyzed the results according to the standard protocol for the
comparative threshold cycle (ΔΔCT) method, using GAPDH as the
endogenous calibrator. For the analysis of tissue expression proﬁles
the expression rates of each gene in different tissues were compared
to the testis and presented as a percentage value (the expression rate
in the testis=100%). The testis was selected as the comparator due to
consistently high expression rates of most of the MT-RNR2-like genes
there. The results of the exposure experiments were presented as
ΔΔCT, which reﬂects a change in expression in response to an agent
compared to an appropriate control (STS vsmedium/beta-carotene vs
medium with a solvent [ethanol and THF]).
Sequencing the MTRNR2L5 gene
In order to establish the relative frequency of the MTRNR2L5
variants we genotyped them by sequencing in 93 unrelated healthy
adults, representing the general Polish population. The use of
anonymized DNA samples was accepted by the local Bioethics
Committee, and the patients provided informed consent to participate
in genotype frequency and gene association studies.
DNA was isolated with the QIAamp DNA Blood Mini Kit (QIAGEN,
Hilden, Germany), the MTRNR2L5 putative coding sequence was
ampliﬁed with the HotStarTaq Plus DNA Polymerase Kit (QIAGEN,
Hilden, Germany), using the following primers: 5′-CCAATACAG-
TCATGCTCTAAGCAA-3′ (forward) and 5′-CTCGTGATCCACCCACCT-3′
(reverse). The PCR product was puriﬁed with QIAquick PCR Puriﬁca-
tion Kit (QIAGEN, Hilden, Germany) and sequenced with BigDye
Terminator 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA, USA). The products of cycle sequencing were cleared of unbound
ﬂuorescent dyes with BigDye XTerminator Puriﬁcation Kit (Applied
Biosystems, Foster City, CA, USA) and separated on the 3130xl Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
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